Neutropenia after rituximab treatment: new insights on a late complication
O Wolach, O Shpilberg, M Lahav - Current opinion in hematology, 2012 - journals.lww.com
O Wolach, O Shpilberg, M Lahav
Current opinion in hematology, 2012•journals.lww.comLON is an increasingly recognized late adverse event of rituximab therapy. Acquaintance
with the incidence, risk factors, natural history, and expected complications of LON may
improve proper clinical management. Many aspects in the clinical management of LON
remain to be answered during further studies aimed at this goal.
with the incidence, risk factors, natural history, and expected complications of LON may
improve proper clinical management. Many aspects in the clinical management of LON
remain to be answered during further studies aimed at this goal.
Summary
LON is an increasingly recognized late adverse event of rituximab therapy. Acquaintance with the incidence, risk factors, natural history, and expected complications of LON may improve proper clinical management. Many aspects in the clinical management of LON remain to be answered during further studies aimed at this goal.
Lippincott Williams & Wilkins